"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
Descriptor ID |
D020123
|
MeSH Number(s) |
D02.540.505.760
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 2 | 2 | 4 |
2001 | 2 | 2 | 4 |
2002 | 2 | 0 | 2 |
2003 | 6 | 4 | 10 |
2004 | 8 | 8 | 16 |
2005 | 12 | 3 | 15 |
2006 | 14 | 3 | 17 |
2007 | 16 | 4 | 20 |
2008 | 7 | 17 | 24 |
2009 | 19 | 11 | 30 |
2010 | 13 | 19 | 32 |
2011 | 19 | 10 | 29 |
2012 | 13 | 16 | 29 |
2013 | 15 | 16 | 31 |
2014 | 20 | 16 | 36 |
2015 | 12 | 14 | 26 |
2016 | 5 | 7 | 12 |
2017 | 4 | 10 | 14 |
2018 | 4 | 6 | 10 |
2019 | 5 | 3 | 8 |
2020 | 3 | 4 | 7 |
2021 | 4 | 2 | 6 |
2022 | 1 | 6 | 7 |
2023 | 0 | 3 | 3 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex. Nat Commun. 2024 Jan 09; 15(1):406.
-
Mammalian target of rapamycin inhibitors: A new-possible approach for in-utero medication therapy. Prenat Diagn. 2024 01; 44(1):88-98.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial. JCI Insight. 2023 04 24; 8(8).
-
Bioresorbable stents: We have more work to do. Catheter Cardiovasc Interv. 2023 05; 101(6):978-979.
-
Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response. Pediatr Blood Cancer. 2023 04; 70(4):e30215.
-
No Association of Sirolimus with Wound Complications in Children With Vascular Anomalies. J Pediatr Surg. 2023 Aug; 58(8):1555-1559.
-
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022 10 01; 107(10):2295-2303.
-
The use of non-model Drosophila species to study natural variation in TOR pathway signaling. PLoS One. 2022; 17(9):e0270436.
-
Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signaling. Cytotherapy. 2022 Dec; 24(12):1201-1210.